SHR-4506 injection for adults with malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SHR-4506 injection is being tested in a Phase 1 dose-escalation study to find the maximum tolerated or maximum administered dose and to characterize safety and tolerability. Eligible adults have histologically or cytologically confirmed malignant tumors, ECOG performance status 0–1, adequate organ function, and have failed or are intolerant of standard therapies. The protocol includes a dose-expansion phase for patients with measurable disease and excludes those with CNS tumor involvement, active autoimmune disease, immunodeficiency, uncontrolled tumor-related pain, or prior exposure to the same drug class. Study visits and treatment are conducted at Ruijin Hospital and Renji Hospital, both affiliated with Shanghai Jiao Tong University School of Medicine in Shanghai.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years, any gender.
2. ECOG performance status 0-1.
3. Histologically or cytologically confirmed malignant tumor patients who have failed standard therapy, or are intolerant to standard therapy, or have no standard treatment available.
4. Adequate organ function.
5. Voluntary participation in this clinical trial, with full understanding of study procedures and ability to provide written informed consent.
6. Expected survival ≥12 weeks.
7. Patients in the dose-expansion phase must have measurable lesions.
8. Agreement to use contraception from the time of signing the informed consent to at least 60 days after the last dose of the investigational drug.

Exclusion Criteria:

1. Prior treatment with the same class of investigational drug.
2. Confirmed or suspected central nervous system (CNS) tumor involvement.
3. Uncontrolled tumor-related pain.
4. Active autoimmune disease, history of immunodeficiency (including primary or secondary, e.g., HIV infection), or autoimmune disorders requiring systemic therapy.
5. Clinically significant cardiovascular disease history.
6. Known hypersensitivity to any component of the investigational drug.
7. Major surgery or significant trauma within 4 weeks prior to the first dose of the investigational drug; diagnostic or superficial surgery within 7 days before the first dose; or planned major surgery during the study period.
8. Adverse events from prior therapy have not recovered to ≤ CTCAE Grade 1.
9. Severe infection within 4 weeks before the first dose, or active infection within 2 weeks.
10. History of cerebrovascular accident within 6 months before the first dose of the investigational drug.
11. Patients with other active malignancies within 2 years prior to the first dose or concurrent malignancies.
12. Patients with any other condition judged by the investigator that makes the patient unsuitable for participation in the study.

Where it's running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting
• Renji Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jie Shen
• Email: jie.shen@hengrui.com
• Phone: +86-0518-81220121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• SHR-9839 alone or with chemotherapy plus adebrelimab in advanced esophageal squamous cell cancer

  This trial tests SHR-9839 by itself or with chemotherapy and adebrelimab to see if it helps people with advanced ESCC.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07751341

• SHR-6914 in adults with prostate cancer

  A early-stage study tests SHR-6914 as a single therapy to see if it is safe and tolerable in adults with prostate cancer.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07735377

• Shr-1501 plus BCG vs placebo plus BCG in high-risk papillary-only NMIBC

  This phase 3 trial tests whether SHR-1501 added to BCG helps people with high-risk papillary-only non-muscle-invasive bladder cancer compared to placebo with BCG.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07726992

• Combination therapy for residual triple-negative breast cancer after neoadjuvant treatment

  This Phase 3 trial tests whether Trastuzumab Rezetecan plus Adebrelimab works better than the investigator’s choice in people with residual invasive triple-negative breast cancer after prior treatment.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07679360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.